GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellectis SA (NAS:CLLS) » Definitions » Return-on-Tangible-Asset
中文

Cellectis (Cellectis) Return-on-Tangible-Asset

: -32.08% (As of Sep. 2023)
View and export this data going back to 2015. Start your Free Trial

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Cellectis's annualized Net Income for the quarter that ended in Sep. 2023 was $-69.93 Mil. Cellectis's average total tangible assets for the quarter that ended in Sep. 2023 was $218.01 Mil. Therefore, Cellectis's annualized Return-on-Tangible-Asset for the quarter that ended in Sep. 2023 was -32.08%.

The historical rank and industry rank for Cellectis's Return-on-Tangible-Asset or its related term are showing as below:

CLLS' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -160.56   Med: -20.45   Max: 0.02
Current: -34.13

During the past 13 years, Cellectis's highest Return-on-Tangible-Asset was 0.02%. The lowest was -160.56%. And the median was -20.45%.

CLLS's Return-on-Tangible-Asset is ranked better than
54.34% of 1555 companies
in the Biotechnology industry
Industry Median: -40.28 vs CLLS: -34.13

Cellectis Return-on-Tangible-Asset Historical Data

The historical data trend for Cellectis's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cellectis Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only -18.94 -21.14 -17.36 -26.93 -33.13

Cellectis Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -38.12 -39.83 -47.06 -17.83 -32.08

Competitive Comparison

For the Biotechnology subindustry, Cellectis's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cellectis Return-on-Tangible-Asset Distribution

For the Biotechnology industry and Healthcare sector, Cellectis's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Cellectis's Return-on-Tangible-Asset falls into.



Cellectis Return-on-Tangible-Asset Calculation

Cellectis's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2022 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2022 )  (A: Dec. 2021 )(A: Dec. 2022 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2022 )  (A: Dec. 2021 )(A: Dec. 2022 )
=-106.139/( (380.223+260.498)/ 2 )
=-106.139/320.3605
=-33.13 %

Cellectis's annualized Return-on-Tangible-Asset for the quarter that ended in Sep. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Sep. 2023 )  (Q: Jun. 2023 )(Q: Sep. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Sep. 2023 )  (Q: Jun. 2023 )(Q: Sep. 2023 )
=-69.928/( (226.979+209.038)/ 2 )
=-69.928/218.0085
=-32.08 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Sep. 2023) net income data.


Cellectis  (NAS:CLLS) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Cellectis Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Cellectis's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Cellectis (Cellectis) Business Description

Traded in Other Exchanges
Address
8, rue de la Croix Jarry, Paris, FRA, 75013
Cellectis SA is a biotechnology company focused on developing immunotherapies for cancer. The company engages in gene editing in an attempt to lead the body's immune system toward attacking cancer cells. Cellectis utilizes strategic corporate partnerships along with cooperation through various university clinical centers. The company's gene-editing technologies allow for the creation of healthy cells derived from healthy donors rather than the patients themselves. It reports two segments: Therapeutics and Plants. Its Therapeutics segment focuses on novel cancer therapies, while its Plants segment focuses on agricultural biotechnology.

Cellectis (Cellectis) Headlines

From GuruFocus

Cellectis Announces Pricing of Follow-On Offering

By Stock market mentor Stock market mentor 02-03-2023